Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Valero Energy Corporation (VLO) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Valero Energy CorporationTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Valero Energy Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Valero Energy Corporation trades at $325.35 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 18.4× ACADIA Pharmaceuticals Inc.'s market cap, and Valero Energy Corporation pays a 1.48% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.

ACADVLO
Market Cap
$5.07B$93.27B
Sector
HealthEnergy
52-Week High
$29.41$323.92
52-Week Low
$20.06$133.38
Enterprise Value
$4.19B$96.74B
Dividend Yield
1.48%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

Valero Energy Corporation

Valero Energy (VLO) trades at $314.95, up 5.58% in 24 hours, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $307 and resistance at $324. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $12.54 surpassing the $10.11 estimate. Revenue for 2026 is projected to rise to $139.4 billion, with net income margin improving to 5.17%.

Outlook remains positive due to robust refining margins and renewable diesel growth, but risks include volatile oil prices and geopolitical tensions. Analysts maintain a buy consensus with a $324.27 price target, indicating potential upside. Investors should monitor execution on earnings guidance and global energy supply dynamics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Valero Energy Corporation

Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.

Read more on VLO